Post Subject #517   HIV controlled with improved CAR T therapy; human marcusl2 10/13/17 11:25:21 AM #516   CTL019 has robust activity in DLBCL and triple-refractory marcusl2 10/10/17 12:21:49 PM #515   Carl June has achieved a complete remission in marcusl2 10/10/17 11:56:52 AM #514   The start of Kymriah expanding. I think that marcusl2 10/04/17 03:16:38 PM #513   Broker Forecast - Peel Hunt issues a broker marcusl2 09/20/17 04:27:16 PM #512   5T4 oncofoetal antigen: an attractive target for immune georgejjl 09/15/17 07:45:47 PM #511   Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide georgejjl 09/15/17 07:40:04 PM #510   http://www.bioworld.com/content/novartis-car-ts-kymriah-market-race-next-gen-win marcusl2 09/08/17 05:56:54 AM #509   https://www.cbsnews.com/news/fda-approves-first-gene-therapy-in-u-s-to-treat-leu marcusl2 09/06/17 04:49:05 PM #508   http://myfox28columbus.com/good-day-columbus/local-doctor-on-how-car-t-cell-ther marcusl2 09/06/17 04:09:03 PM #507   The treatment, Kymriah, developed with British Aim-listed biotech marcusl2 09/04/17 01:28:00 PM #506   http://whyy.org/cms/radiotimes/ marcusl2 09/03/17 03:32:57 PM #505   https://www.streetwisereports.com/pub/na/small-cap-biotech-benefits-from-first-f marcusl2 09/02/17 11:00:43 AM #504   A big THANK YOU should go to Emily georgejjl 08/30/17 09:23:26 PM #503   FDA announces first US gene therapy approval for georgejjl 08/30/17 08:09:15 PM #502   The FDA approval press release!!! georgejjl 08/30/17 12:28:04 PM #501   FDA approved the Novartis and Oxford BioMedica treatment georgejjl 08/30/17 12:17:43 PM #500   But with a market value of a little georgejjl 08/29/17 08:59:16 PM #499   CAR T 5T4 marcusl2 08/28/17 02:02:26 PM #498   As previously reported, BTIG upgraded Juno Therapeutics to marcusl2 08/28/17 02:01:50 PM #497   How do you turn world-leading British science into medicines? marcusl2 08/27/17 05:19:03 AM #496   http://www.dailymail.co.uk/wires/reuters/article-4816352/Profit-finally-sight-ge marcusl2 08/23/17 11:21:08 AM #495   http://www.oxfordbiomedica.co.uk/system/files/webcasts-and-audios/interimresults marcusl2 08/17/17 07:33:39 AM #494   CTL019 and other undisclosed CART products; over $100 marcusl2 08/17/17 04:03:47 AM #493   HTTPS://www.pennmedicine.org/cancer/navigating-cancer-care/treatment-types/immun marcusl2 08/15/17 05:04:30 AM #492   Today's Independent: marcusl2 08/15/17 04:04:02 AM #491   Two CAR T-cell therapy products, in fact, are marcusl2 08/12/17 03:59:06 PM #490   http://time.com/4895010/cancers-newest-miracle-cure/?utm_source=time.com&utm_med marcusl2 08/12/17 10:49:32 AM #489   2 million pounds is better than nothing but georgejjl 08/11/17 11:11:28 AM #488   This will hopefully lead to improved manufacturing; marcusl2 08/11/17 03:39:35 AM #487   London, UK - 07 August 2017: Oxford BioMedica marcusl2 08/09/17 03:49:53 AM #486   http://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-annou marcusl2 08/07/17 04:33:46 AM #485   Immune Design's results appear to be very promising ; marcusl2 08/03/17 06:22:55 AM #484   ADA–SCID This is a partner's product, where Oxford Biomedica georgejjl 08/03/17 12:02:04 AM #483   A single dose of peripherally infused EGFRvIII-directed CAR georgejjl 08/02/17 11:09:24 PM #482   georgejjl Saturday, 01/28/17 11:27:04 AM georgejjl 08/02/17 10:53:48 PM #481   "It's rare to hear regulators refer to the marcusl2 08/02/17 08:00:53 AM #480   Yes I listened to the meeting live, very marcusl2 08/02/17 08:00:09 AM #479   Marcus, That was truly amazing. georgejjl 08/01/17 10:12:24 PM #478   From page 46, CM 17, impressive from OXB marcusl2 08/01/17 12:53:58 PM #477   Profits with I--- will go to buy some here. JUST 10-11-12 08/01/17 08:09:56 AM #476   OXB-302 Gene-based immunotherapy targeting a range of cancers georgejjl 07/27/17 07:19:01 PM #475   Oxford Biomedica has the ability to deliver the marcusl2 07/26/17 04:15:36 PM #474   BCMA CAR T being done by Bluebird, Penn marcusl2 07/26/17 07:38:45 AM #473   OXB own 4% plus supply the Lenti marcusl2 07/24/17 04:11:45 PM #472   https://www.nytimes.com/2017/07/23/health/gene-therapy-cancer.html marcusl2 07/24/17 11:53:07 AM #471   Too many me thinks JUST 10-11-12 07/18/17 09:52:40 PM #470   Oxford BioMedica currently has 3.09 billion shares outstanding. georgejjl 07/18/17 09:22:50 PM #469   Novartis is looking for acquisitions in the $2 georgejjl 07/18/17 08:59:17 PM #468   Re acquisitions, listen to 4mins. marcusl2 07/18/17 08:45:51 AM Post Subject

© 2017 InvestorsHub.Com, Inc.